<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">55164</article-id><article-id pub-id-type="doi">10.7554/eLife.55164</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-171574"><name><surname>Worth</surname><given-names>Amy A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171575"><name><surname>Shoop</surname><given-names>Rosemary</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3617-4358</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171576"><name><surname>Tye</surname><given-names>Katie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171577"><name><surname>Feetham</surname><given-names>Claire H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171578"><name><surname>D'Agostino</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171579"><name><surname>Dodd</surname><given-names>Garron T</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-144148"><name><surname>Reimann</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116453"><name><surname>Gribble</surname><given-names>Fiona M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171580"><name><surname>Beebe</surname><given-names>Emily C</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-171581"><name><surname>Dunbar</surname><given-names>James D</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-171582"><name><surname>Alexander-Chacko</surname><given-names>Jesline T</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-171583"><name><surname>Sindelar</surname><given-names>Dana K</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-171585"><name><surname>Coskun</surname><given-names>Tamer</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-171584"><name><surname>Emmerson</surname><given-names>Paul J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" corresp="yes" id="author-171322"><name><surname>Luckman</surname><given-names>Simon M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5318-5473</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf8"/></contrib><aff id="aff1"><institution content-type="dept">Faculty of Biology, Medicine and Health</institution>, <institution>University of Manchester</institution>, <addr-line><named-content content-type="city">Manchester</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Department of Physiology</institution>, <institution>University of Melbourne</institution>, <addr-line><named-content content-type="city">Melbourne</named-content></addr-line>, <country>Australia</country></aff><aff id="aff3"><institution content-type="dept">Wellcome Trust MRC Institute of Metabolic Science</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff4"><institution content-type="dept">Lilly Research Laboratories, Lilly Corporate Center</institution>, <institution>Eli Lilly and Company</institution>, <addr-line><named-content content-type="city">Indianapolis</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1155"><name><surname>Palmiter</surname><given-names>Richard D</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, University of Washington</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>simon.luckman@manchester.ac.uk</email> (SL);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>07</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e55164</elocation-id><history><date date-type="received"><day>14</day><month>01</month><year>2020</year></date><date date-type="accepted"><day>26</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Worth et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Worth et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-55164-v1.pdf"/><abstract><p>The cytokine, GDF15, is produced in pathological states which cause cellular stress, including cancer. When over expressed, it causes dramatic weight reduction, suggesting a role in disease-related anorexia. Here we demonstrate that the GDF15 receptor, GFRAL, is located in a subset of cholecystokinin neurons which span the area postrema and the nucleus of the tractus solitarius of the mouse. GDF15 activates GFRAL<sup>AP/NTS</sup> neurons and supports conditioned taste and place aversions, while the anorexia it causes can be blocked by a monoclonal antibody directed at GFRAL or by disrupting CCK neuronal signalling. The cancer-therapeutic drug, cisplatin, induces the release of GDF15 and activates GFRAL<sup>AP/NTS</sup> neurons, as well as causing significant reductions in food intake and body weight in mice. These metabolic effects of cisplatin are abolished by pre-treatment with the GFRAL monoclonal antibody. Our results suggest that GFRAL neutralising antibodies or antagonists may provide a co-treatment opportunity for patients undergoing chemotherapy.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Rat</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/M001067/1</award-id><principal-award-recipient><name><surname>Luckman</surname><given-names>Simon M</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/L021129/1</award-id><principal-award-recipient><name><surname>Luckman</surname><given-names>Simon M</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/R002991/1</award-id><principal-award-recipient><name><surname>Luckman</surname><given-names>Simon M</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/P009824/2</award-id><principal-award-recipient><name><surname>D'Agostino</surname><given-names>Giuseppe</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Emily C Beebe, Paid employee of Eli Lilly..</p></fn><fn fn-type="conflict" id="conf3"><p>James D Dunbar, Paid employee of Eli Lilly..</p></fn><fn fn-type="conflict" id="conf4"><p>Jesline T Alexander-Chacko, Paid employee of Eli Lilly..</p></fn><fn fn-type="conflict" id="conf5"><p>Dana K Sindelar, Paid employee of Eli Lilly..</p></fn><fn fn-type="conflict" id="conf6"><p>Tamer Coskun, Paid employee of Eli Lilly..</p></fn><fn fn-type="conflict" id="conf7"><p>Paul J Emmerson, Paid employee of Eli Lilly..</p></fn><fn fn-type="conflict" id="conf8"><p>Simon M Luckman, BB/S008098/1 is a BBSRC Industrial Partnership Award between SML and Eli Lilly.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All procedures were conducted in accordance with either: the United Kingdom Animals (Scientific Procedures) Act, 1986 (ASPA) and approved by the local animal welfare ethical review body (AWERB); the Eli Lilly Institutional Animal Care and Use Committee (IACUC) in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals; or the University of Melbourne Animal Ethics Committee (1914919) and conformed to National Health &amp; 8 Medical Research Council (Australia) guidelines regarding the care and use of experimental animals. Additional guidance from the UK National Centre for 3R's (NC3Rs) was followed where applicable.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><supplementary-material><ext-link xlink:href="elife-55164-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>